Elie G Dib

9PUBLICATIONS
55CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)Cancer genetics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (9)

|Apr 30, 2026
Pertuzumab and Trastuzumab in Patients With ERBB2/3-Altered Urothelial or Ovary/Fallopian Tube Cancer: Results From the Targeted Agent and Profiling Utilization Registry Study.

|Apr 30, 2026
Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.

|Jan 13, 2026
Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005.

Kristin A Higgins, Chen Hu, Helen J Ross

|May 15, 2024
Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Timothy L Cannon, Michael Rothe, Pam K Mangat

|Apr 16, 2024
Granulomatous hepatitis: Is it bugs, drugs, or other untoward culprits?

Neil Shah, Elie G Dib, Nora Joseph

|Apr 11, 2024
Regorafenib in Patients With Solid Tumors With BRAF Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.

Vaibhav Sahai, Michael Rothe, Pam K Mangat

Pageof 2

Frequent Collaborators

6 joint publications

Susan Halabi

6 joint publications

Elizabeth Garrett-Mayer

6 joint publications

Pam K Mangat

6 joint publications

Gina N Grantham